Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
"Clinician, Consumer",Dupilumab,"Moderate to severe atopic dermatitis, following 2nd line treatment(s)",Dupilumab (Dupixent),Recommended for decline,Community and Hospital,Dermatologicals
